Advancing Antibody Therapeutics to the Clinic
The Oncology Stream at PEGS is back to share what is new and exciting in the fight against cancer, and the antibody developments that are leading the charge. Drug discovery in oncology has long relied on antibodies and antibody-based products as a tool
to achieve therapeutic success. Bispecific antibodies, cell engagers, ADCs, nanobodies and combinatorial therapies are being explored to improve targeted therapy and drug delivery. This year, we are adding a new conference on Emerging Targets and Novel Targets for Oncology & Beyond,
which will look at hot targets, re-emergence of old targets, as well as unconventional or alternative approaches for cancer therapy. Together, the 3 conferences in this stream will present a comprehensive look at strategies driving toward clinical
success.
Conferences Include:
May 2-3
Antibodies for Cancer Therapy
May 3-4
Emerging Targets and Novel Approaches for Oncology & Beyond
May 5-6
Driving Clinical Success in Antibody Drug Conjugates
Keynote Presentations:
Targeting Myeloma Cells with Nanobody-Based Heavy Chain Antibodies, Bispecific Killer Cell Engagers, CAR-NK Cells, and AAV Vectors
Friedrich Koch-Nolte, PhD, Professor, Immunology & Molecular Biology, Institute of Immunology, University Medical Center
Hamburg-Eppendorf
The Renaissance of Antibody-Drug conjugates - Progress, Challenges and the Future
Puja Sapra, PhD, SVP, Biologics Engineering & Oncology Targeted Delivery, AstraZeneca Pharmaceuticals Inc.
On-Targets and Off-Targets of Peptide-MHC Reactive Agents
David A. Scheinberg, MD, PhD, Vincent Astor Chair & Director, Molecular Pharmacology Program and Center for Experimental Therapeutics, Deputy Director, Sloan Kettering
Institute for Therapeutic Discovery, Memorial Sloan Kettering Cancer Center
Zynlonta – In 5 Years from FIH to Regulatory Approval: Lessons Learnt from the Preclinic, Phase 1 and Phase 2 Studies
David Ungar, MD, Head of US Oncology Clinical Development, ADC Therapeutics